Belite Bio Aims for NDA Submission by H1 2026 with Robust Cash Runway and Advancing Phase III Trials

Belite Bio plans to submit a New Drug Application (NDA) for Tinlarebant in H1 2026. The company reported strong progress in Phase III trials and has a robust cash runway. Tinlarebant has been designated as a breakthrough, rare pediatric disease, Fast Track, and Pioneer product. These designations could potentially expedite the regulatory approval process.

Title: Belite Bio Targets NDA Submission for Tinlarebant in H1 2026

Belite Bio (BLTE) has made significant strides in advancing its pipeline, particularly with its drug candidate Tinlarebant. The company plans to submit a New Drug Application (NDA) for Tinlarebant in the first half of 2026. This move is supported by strong progress in Phase III trials and a robust cash position.

Tinlarebant has received multiple designations that could expedite the regulatory approval process. It is designated as a breakthrough therapy, a rare pediatric disease, a Fast Track product, and a Pioneer product. These designations are particularly noteworthy as they indicate the drug's potential to address unmet medical needs.

The company reported excellent progress in the second quarter of 2025 towards advancing Tinlarebant in patients living with Stargardt's disease and geographic atrophy. The Data Safety Monitoring Board completed its interim analysis for the DRAGON trial and recommended that the trial proceed without modifications. This positive development suggests that the drug is showing promising results.

Belite Bio expects to complete the DRAGON study in the fourth quarter of 2025 and submit the final data for regulatory review. The company also expects to complete enrollment for the DRAGON II trial by the end of 2025. Additionally, the Phase III global study in geographic atrophy recently completed enrollment with 529 subjects.

The company's financial health is also robust. Belite Bio raised $15 million in gross proceeds through a registered direct offering in August 2025 and has a strong balance sheet with 4 years of cash runway. For the second quarter of 2025, the company reported R&D expenses of $11 million, G&A expenses of $6.5 million, and a net loss of $16.3 million. The majority of the increase in expenses came from share-based compensation, which was $7.6 million and not cash-related. The operating cash outflow was only $8.6 million.

Belite Bio remains confident in its ability to complete all Phase III trials with its current cash position. The company expects to be able to complete all 3 Phase III trials with its current cash, and it still expects 4 years of cash runway without considering commercialization costs.

Management has emphasized the strength of the balance sheet and the company's progress in meeting regulatory milestones. The company's tone continues to show cautious optimism, with recurring questions on trial timelines, regulatory engagement, and financial sustainability.

References
[1] https://seekingalpha.com/news/4483626-belite-bio-targets-nda-submission-for-tinlarebant-in-first-half-of-2026-amid-strong-cash
[2] https://www.quiverquant.com/news/Belite+Bio%2C+Inc.+Receives+Breakthrough+Therapy+Designation+for+Tinlarebant+in+Stargardt+Disease%3B+Announces+Q2+2025+Financial+Results+and+Upcoming+Milestones